Related Experiment Videos
Antitumor effect of TNP-470 on glial tumors transplanted in rats
1Department of Neurosurgery, Hiroshima University School of Medicine, Japan.
Abstract:
Anti-angiogenic agents were be clinically useful for the therapy of solid tumors, as the growth and proliferation of tumors require neovascularization. Previous reports have been made on the antitumor effect of TNP-470, an angiogenic inhibitor, on medulloblastomas implanted subcutaneously into nude mice. The present study was undertaken for the purpose of investigating possible antitumor effects on two model subcutaneous and intracranial tumors transplanted into rats. 9-L gliosarcomas were transplanted into the left femoral region subcutaneously and the left frontal region of Fisher 344 female rats, and the TNP-470 was then administered subcutaneously. The rats were divided into two treatment groups and a control group. TNP-470 resulted in dose-dependent inhibition of 9-L gliosarcoma growth and also prolonged survival in treatment groups. Therefore TNP-470 was considered to be effective for the treatment of malignant brain tumors, although it caused dose-dependent decreases in body weight.
Insights
TNP-470, an anti-angiogenic agent, effectively inhibited 9-L gliosarcoma growth in rats, showing promise for treating malignant brain tumors. This study demonstrated dose-dependent tumor inhibition and prolonged survival, despite some weight loss.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Solid tumor growth necessitates neovascularization, making anti-angiogenic agents a potential therapeutic strategy.
- Previous studies indicated TNP-470's efficacy against medulloblastomas in mice.
- The study aimed to evaluate TNP-470's effects on gliosarcoma models in rats.
Purpose of the Study:
- To investigate the antitumor effects of TNP-470 on subcutaneous and intracranial 9-L gliosarcoma models in rats.
- To assess the dose-dependent efficacy and survival impact of TNP-470 treatment.
- To determine the therapeutic potential of TNP-470 for malignant brain tumors.
Main Methods:
- 9-L gliosarcomas were implanted subcutaneously and intracranially into Fisher 344 female rats.
- Rats were divided into two TNP-470 treatment groups and a control group.
- TNP-470 was administered subcutaneously, and tumor growth and survival were monitored.
Main Results:
- TNP-470 demonstrated dose-dependent inhibition of 9-L gliosarcoma growth.
- Treatment with TNP-470 significantly prolonged survival in the treated groups compared to the control.
- A dose-dependent decrease in body weight was observed in the TNP-470 treated rats.
Conclusions:
- TNP-470 exhibits significant antitumor activity against 9-L gliosarcoma in a rat model.
- The findings suggest TNP-470 is a potential therapeutic agent for malignant brain tumors.
- Further research is warranted to optimize dosage and manage side effects like weight loss.